ReViral Ltd Appoints Seth Hetherington as Chief Medical Officer as It Prepares Its Lead RSV Candidate to Enter Pediatric Phase IIa Clinical Trials - Business Wire
ReViral Ltd Appoints Seth Hetherington as Chief Medical Officer as It Prepares Its Lead RSV Candidate to Enter Pediatric Phase IIa Clinical Trials Business Wire
ReViral Ltd., a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV), today announce.
Comments
Post a Comment